FACIT provides $3 mln in seed funding to Propellon Therapeutics
Toronto biotechnology startup Propellon Therapeutics has raised $3 million in seed-stage financing. The investment was made by Fight Against Cancer Innovation Trust (FACIT), an affiliate of the Ontario Institute for Cancer Research. FACIT established Propellon last year to develop a portfolio of WDR5-targeted anti-cancer therapeutics. The funds raised will allow it to accelerate the nomination of a candidate drug and prepare for a Series A financing or strategic partnership to back clinical trials. Earlier this week, FACIT launched a new fund to support Ontario oncology discoveries.
22 March 2017•3 mins read
